Skip to main content
Clinical Trials/NL-OMON32289
NL-OMON32289
Completed
Phase 3

A randomized clinical trial of surgery or radiosurgery (stereotactic radiotherapy) in patients with stage IA non-small cell lung cancer who are fit to undergo primary resection - Randomized trial of surgery or radiosurgery in stage IA lung cancer

Vrije Universiteit Medisch Centrum0 sites960 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
stage IA NSCLC
Sponsor
Vrije Universiteit Medisch Centrum
Enrollment
960
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age \* 18 years;Patients with a diagnosis of stage IA non\-cell lung cancer diagnosed in accordance with Dutch CBO guidelines. When no pathological diagnosis is available, a patient with a new or growing pulmonary lesion with radiological features consistent with malignancy AND a lesion showing uptake on a FDG\-PET scan will be eligible. ;No evidence of regional or distant metastases on a standardized FDG\-PET scan within 6 weeks of any protocol treatment .;Medial extension of tumours should be least 2 cm away from main and lobar bronchi, and also minimum of 1\.5 cm from large peripheral blood vessels such as the aorta and main pulmonary artery. Lesions of at least 2 cm from the mediastinal pleura will be eligible if the responsible radiation oncologist judges that the specified normal tissue tolerance doses specified in the protocol will not be exceeded.;Patients should be fit to undergo both surgery and SRT. ;Patients who are judged by a multi\-disciplinary team to have 2 primary lung tumors (on the basis of clinical, radiological, FDG\-PET and/or cyto\-pathology findings) are eligible for randomization provided that both surgery and SRT can be performed in accordance with protocol requirements.;Patient should be fit to undergo a complete surgical resection of the lesion in accordance with Dutch CBO guidelines \[2004] ;Performance score of ECOG \* 2 before any treatment.;Able to comply with post\-treatment follow\-up

Exclusion Criteria

  • Prior chemotherapy or radiotherapy for the present diagnosis of NSCLC. ;History of any active malignancy (other than NSCLC) unless treated more than 3 years with curative intent and no recurrence, with the exception of non\-melanoma skin cancers or in\-situ cervical cancers.;Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, severe cardiac arrhythmia requiring medication, hepatic, renal or metabolic disease).;Concomitant treatment with any other experimental drug under investigation.

Outcomes

Primary Outcomes

Not specified

Similar Trials